Skip to main content

Animations

MJFF Publications

2421 - 2430 of 6433 Results
Title
Year
  • Year
  • 2010
  • 2010
  • 2011
  • 2015
  • 2016
  • 2015
  • 2014
  • 2010
  • 2010
  • 2014
  • Summary Details
    OPEN
    Title: Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.nbd.2010.07.010
    Citation Count: 266
  • Summary Details
    OPEN
    Title: LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.nbd.2010.04.002
    Citation Count: 143
  • Summary Details
    OPEN
    Title: Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-sa
    DOI - Digital Object Identifier: 10.1038/ncomms1453
    Citation Count: 445
  • Summary Details
    OPEN
    Title: Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/ncomms8314
    Citation Count: 280
  • Summary Details
    OPEN
    Title: Impairment of PARK14-dependent Ca2+ signalling is a novel determinant of Parkinson’s disease
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/ncomms10332
    Citation Count: 94
  • Summary Details
    OPEN
    Title: O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease
    Journal Name: Nature Chemistry
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/nchem.2361
    Citation Count: 253
  • Summary Details
    OPEN
    Title: A GCase Chaperone Improves Motor Function in a Mouse Model of Synucleinopathy
    Journal Name: Neurotherapeutics
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s13311-014-0294-x
    Citation Count: 98
  • Summary Details
    OPEN
    Title: Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders
    Journal Name: Acta Neuropathologica
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s00401-010-0664-3
    Citation Count: 795
  • Summary Details
    OPEN
    Title: Heterogeneous neuropathological findings in Parkinson’s disease with mild cognitive impairment
    Journal Name: Acta Neuropathologica
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s00401-010-0744-4
    Citation Count: 84
  • Summary Details
    OPEN
    Title: Latent growth-curve analysis reveals that worsening Parkinson’s disease quality of life is driven by depression.
    Journal Name: Neuropsychology
    Publisher: American Psychological Association (APA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1037/neu0000158
    Citation Count: 20
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.